Results 81 to 90 of about 3,056 (181)

Interpretation of clinical application recommendations for anti-Aβ monoclonal antibodies （2025 Edition） [PDF]

Zhenduanxue lilun yu shijian
The Clinical Application Recommendations for Anti-Aβ Monoclonal Antibodies (2025 Edition) systema-tically integrates Phase Ⅲ clinical trial data for aducanumab, lecanemab, and donanemab, referencing relevant drug labels, domestic real-world evidence, and
ZHI Nan, GENG Jieli, CAO Wenwei, SONG Yaying, WANG Gang
doaj   +1 more source

Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review

Journal of Education, Health and Sport
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for ...
Agnieszka Skoczeń, Natalia Rutecka, Błażej Kaczmarek, Agata Kuśnierz-Gibała, Adrian Kruk, Michał Kulesza, Weronika Wawrzynów, Martyna Miłoś, Aleksandra Dorosz, Magdalena Maria Jakubowska   +9 more
doaj   +1 more source

Proposing a Coverage With Evidence Development Framework for Accelerated Approval at the U.S. Food and Drug Administration

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 9, September 2026.
Dhanush Bearelly, Purav Desai, David T. Zhu, Rajesh Balkrishnan   +3 more
wiley   +1 more source

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease

Biomedicines
Alzheimer’s Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of amyloid beta1-40 and 1-42, and intracellular ...
Xiaoming Qi, Damir Nizamutdinov, Song Stephen Yi, Erxi Wu, Jason H. Huang   +4 more
doaj   +1 more source

Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab

Neurology International
Background/Objectives: Alzheimer disease (AD) causes progressive cognitive and functional loss and substantial caregiver and healthcare burden. Anti-amyloid monoclonal antibodies represent a shift toward biology-directed treatment in biomarker-confirmed ...
Ülkü Figen Demir, Fatmanur Karakuş Dilbaz   +1 more
doaj   +1 more source

Perspective: Minimally clinically important “symptomatic” benefit associated with disease modification resulting from anti‐amyloid immunotherapy

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Despite some skepticism regarding the amyloid hypothesis, there is growing evidence that clearing amyloid by targeting specific species of amyloid (plaque, oligomers, fibrils, and protofibrils) for removal has therapeutic benefits. Specifically, there is
John Alam, Marwan N. Sabbagh
doaj   +1 more source

Posterior Reversible Encephalopathy Syndrome Following Donanemab Infusion: A Novel Adverse Effect in Alzheimer\u27s Disease Therapy

Background: Donanemab (Kisunla) is a monoclonal antibody targeting amyloid-beta used for early Alzheimer\u27s disease (AD). Amyloid-related imaging abnormalities (ARIA) are known adverse effects, but association with posterior reversible encephalopathy ...
Mcphail Ciufo, Mary M, Min, Jiangyong, HajAissa, Naser, Shehaj, Aldo   +3 more
core   +1 more source

FDA's New Approval: Kisunla (Donanemab-Azbt) - A Major Breakthrough in Alzheimer’s Care

Journal of the Pakistan Medical Association
Madam, Alzheimer’s disease, the most pervasive form of dementia, is a neurodegenerative disorder that relentlessly erodes memory, reasoning and judgment.
Zara Babar, Areesha Babar
doaj   +1 more source

Efficacy and Potential of Donanemab: New Treatment Approved for Alzheimer's Disease

La enfermedad de Alzheimer (EA) es la principal causa mundial de demencia, afectando a millones de personas y teniendo un impacto significativo en la salud pública y la calidad de vida de los pacientes y sus familias.
Salgado Feijoo, Alejandro Alfredo, Briones Morales, Victor Euclides, Morocho López, Ana Cristina   +2 more
core   +1 more source

Efficacy and Safety of Recently Approved Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Meta-Analysis

International Journal of Medical Students
Background Alzheimer's disease (AD) is the leading cause of dementia worldwide and affects over 55 million people.  Lecanemab and donanemab are anti-amyloid monoclonal antibodies that flag the abnormal amyloid-beta plaques for removal by the ...
Hassan Khalid, Mohammed Murtada
doaj